Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
McKinsey
Express Scripts
McKesson
Moodys

Last Updated: December 16, 2019

DrugPatentWatch Database Preview

ENLON-PLUS Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Enlon-plus patents expire, and when can generic versions of Enlon-plus launch?

Enlon-plus is a drug marketed by Mylan Institutional and is included in two NDAs.

The generic ingredient in ENLON-PLUS is atropine sulfate; edrophonium chloride. There are twenty-three drug master file entries for this compound. Additional details are available on the atropine sulfate; edrophonium chloride profile page.

Summary for ENLON-PLUS
Drug patent expirations by year for ENLON-PLUS
Synonyms for ENLON-PLUS
(3-hydroxyphenyl)dimethylethylammonium
116-38-1 (cloride)
3-hydroxy-N,N-dimethyl-N-ethylanilinium
312-48-1
70FP3JLY7N
AB00053796
AB00053796_15
AC1L1FEK
AC1Q7AIY
AJ-08009
BC224295
BDBM120262
Benzenaminium, N-ethyl-3-hydroxy-N,N-dimethyl-
BPBio1_000008
BSPBio_000006
BSPBio_002386
C06976
C10H16NO.Cl
CAS-116-38-1
CCG-204602
CHEBI:251408
CHEMBL1104
cid_8307
CJ-00045
Cyclopropanamine, 2-phenyl-, hydrochloride (1:1), (1S,2R)-
DB01010
DivK1c_000809
DTXSID4046943
EDR
Edrophone Chloride
edrophonium
Edrophonium Chloride, 3
EDROPHONIUM ION
Edrophonum
Edroponium
Enlon
Enlon Plus
Ethyl-(3-hydroxy-phenyl)-dimethyl-ammonium
ethyl-(3-hydroxyphenyl)-dimethylazanium
GTPL9073
IDI1_000809
KBio1_000809
KBio2_000922
KBio2_003490
KBio2_006058
KBioGR_001032
KBioSS_000922
Lopac-E-3256
Lopac0_000511
LS-174330
MCULE-5963849469
N-ethyl-3-hydroxy-N,N-dimethylanilinium
N-ethyl-3-hydroxy-N,N-dimethylbenzenaminium
NCGC00015409-01
NCGC00015409-02
NCGC00015409-03
NCGC00015409-04
NCGC00015409-05
NCGC00015409-06
NCGC00015409-07
NCGC00015409-08
NCGC00023975-03
NINDS_000809
Prestwick0_000083
Prestwick1_000083
Prestwick2_000083
Prestwick3_000083
Reversol
SCHEMBL34790
SPBio_001220
SPBio_001945
Spectrum_000442
Spectrum2_001110
Spectrum4_000736
Spectrum5_001531
Tensilon
UNII-70FP3JLY7N
VWLHWLSRQJQWRG-UHFFFAOYSA-O
ZINC1341

US Patents and Regulatory Information for ENLON-PLUS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Institutional ENLON-PLUS atropine sulfate; edrophonium chloride INJECTABLE;INJECTION 019677-001 Nov 6, 1991 DISCN No No   Start Trial   Start Trial   Start Trial
Mylan Institutional ENLON-PLUS atropine sulfate; edrophonium chloride INJECTABLE;INJECTION 019678-001 Nov 6, 1991 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ENLON-PLUS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Institutional ENLON-PLUS atropine sulfate; edrophonium chloride INJECTABLE;INJECTION 019677-001 Nov 6, 1991   Start Trial   Start Trial
Mylan Institutional ENLON-PLUS atropine sulfate; edrophonium chloride INJECTABLE;INJECTION 019678-001 Nov 6, 1991   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Merck
Moodys
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.